# Advances in Research of Adult Gliomas

**Authors:** Alina Finch, Georgios Solomou, Victoria Wykes, Ute Pohl, Chiara Bardella, Colin Watts

PMC · DOI: 10.3390/ijms22020924 · International Journal of Molecular Sciences · 2021-01-18

## TL;DR

This review discusses recent progress in understanding adult brain tumors called gliomas and explores new models and treatments for better diagnosis and monitoring.

## Contribution

The paper provides a comprehensive summary of recent advances in glioma research using new models and techniques.

## Key findings

- In vitro and in vivo models have improved understanding of glioma development and progression.
- 3D organoids and organotypic slices are being used to study glioma heterogeneity and gene expression.
- In silico models and clinical trials are advancing early diagnosis and disease monitoring for gliomas.

## Abstract

Diffuse gliomas are the most frequent brain tumours, representing 75% of all primary malignant brain tumours in adults. Because of their locally aggressive behaviour and the fact that they cannot be cured by current therapies, they represent one of the most devastating cancers. The present review summarises recent advances in our understanding of glioma development and progression by use of various in vitro and in vivo models, as well as more complex techniques including cultures of 3D organoids and organotypic slices. We discuss the progress that has been made in understanding glioma heterogeneity, alteration in gene expression and DNA methylation, as well as advances in various in silico models. Lastly current treatment options and future clinical trials, which aim to improve early diagnosis and disease monitoring, are also discussed.

## Full-text entities

- **Genes:** RET (ret proto-oncogene) [NCBI Gene 5979] {aka CDHF12, CDHR16, HSCR1, MEN2A, MEN2B, MTC1}, Akt1 (Akt serine/threonine kinase 1) [NCBI Gene 11651] {aka Akt, LTR-akt, PKB, PKB/Akt, PKBalpha, Rac}, RB1 (RB transcriptional corepressor 1) [NCBI Gene 5925] {aka OSRC, PPP1R130, RB, p105-Rb, p110-RB1, pRb}, CIC (capicua transcriptional repressor) [NCBI Gene 23152] {aka MRD45}, ALKBH1 (alkB homolog 1, histone H2A dioxygenase) [NCBI Gene 8846] {aka ABH, ABH1, ALKBH, alkB, hABH}, Gfap (glial fibrillary acidic protein) [NCBI Gene 14580], Rag2 (recombination activating gene 2) [NCBI Gene 19374] {aka Rag-2}, TXK (TXK tyrosine kinase) [NCBI Gene 7294] {aka BTKL, PSCTK5, PTK4, RLK, TKL}, MDM4 (MDM4 regulator of p53) [NCBI Gene 4194] {aka BMFS6, HDMX, MDMX, MRP1}, Egf (epidermal growth factor) [NCBI Gene 13645], TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, Mr1 (major histocompatibility complex, class I-related) [NCBI Gene 15064] {aka H2ls}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, Cd86 (CD86 antigen) [NCBI Gene 12524] {aka B7, B7-2, B7.2, B70, CLS1, Cd28l2}, COL4A5 (collagen type IV alpha 5 chain) [NCBI Gene 1287] {aka ASLN, ATS, ATS1, CA54}, HLA-C (major histocompatibility complex, class I, C) [NCBI Gene 3107] {aka D6S204, HLA-JY3, HLAC, HLC-C, MHC, PSORS1}, IDH2 (isocitrate dehydrogenase (NADP(+)) 2) [NCBI Gene 3418] {aka D2HGA2, ICD-M, IDH, IDH-2, IDHM, IDP}, CLDN15 (claudin 15) [NCBI Gene 24146], PIK3R1 (phosphoinositide-3-kinase regulatory subunit 1) [NCBI Gene 5295] {aka AGM7, GRB1, IMD36, p85, p85-ALPHA, p85alpha}, PDGFRB (platelet derived growth factor receptor beta) [NCBI Gene 5159] {aka CD140B, IBGC4, IMF1, JTK12, KOGS, OPDKD}, CDK6 (cyclin dependent kinase 6) [NCBI Gene 1021] {aka MCPH12, PLSTIRE}, GPC3 (glypican 3) [NCBI Gene 2719] {aka DGSX, GTR2-2, MXR7, OCI-5, SDYS, SGB}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, EGF (epidermal growth factor) [NCBI Gene 1950] {aka HOMG4, URG}, MGMT (O-6-methylguanine-DNA methyltransferase) [NCBI Gene 4255], SLTM (SAFB like transcription modulator) [NCBI Gene 79811] {aka Met}, GJA1 (gap junction protein alpha 1) [NCBI Gene 2697] {aka AVSD3, CMDR, CX43, EKVP, EKVP3, GJAL}, Cd80 (CD80 antigen) [NCBI Gene 12519] {aka B71, Cd28l, Ly-53, Ly53, MIC17, TSA1}, Nes (nestin) [NCBI Gene 18008] {aka ESTM46, Ifaprc2, Marc2, RC2}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, CTSS (cathepsin S) [NCBI Gene 1520], Egfr (epidermal growth factor receptor) [NCBI Gene 13649] {aka 9030024J15Rik, Erbb, Errb1, Errp, Wa5, wa-2}, PTEN (phosphatase and tensin homolog) [NCBI Gene 5728] {aka 10q23del, BZS, CWS1, DEC, GLM2, MHAM}, HRAS (HRas proto-oncogene, GTPase) [NCBI Gene 3265] {aka C-BAS/HAS, C-H-RAS, C-HA-RAS1, CTLO, H-RASIDX, HAMSV}, Trp53 (transformation related protein 53) [NCBI Gene 22059] {aka Tp53, bbl, bfy, bhy, p44, p53}, Cd40lg (CD40 ligand) [NCBI Gene 21947] {aka CD154, CD40-L, Cd40l, HIGM1, IGM, IMD3}, Nf1 (neurofibromin 1) [NCBI Gene 18015] {aka Dsk9, E030030H24Rik, Mhdadsk9, Nf-1}, PRKN (parkin RBR E3 ubiquitin protein ligase) [NCBI Gene 5071] {aka AR-JP, LPRS2, PARK2, PDJ}, IL4 (interleukin 4) [NCBI Gene 3565] {aka BCGF-1, BCGF1, BSF-1, BSF1, IL-4}, TERT (telomerase reverse transcriptase) [NCBI Gene 7015] {aka CMM9, DKCA2, DKCB4, EST2, PFBMFT1, TCS1}, Dnmt1 (DNA methyltransferase 1) [NCBI Gene 13433] {aka Cxxc9, Dnmt, Dnmt1o, MCMT, MTase, Met-1}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, AKT3 (AKT serine/threonine kinase 3) [NCBI Gene 10000] {aka MPPH, MPPH2, PKB-GAMMA, PKBG, PRKBG, RAC-PK-gamma}, Idh1 (isocitrate dehydrogenase 1 (NADP+), soluble) [NCBI Gene 15926] {aka E030024J03Rik, Id-1, Idh-1, Idpc}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, PDGFRA (platelet derived growth factor receptor alpha) [NCBI Gene 5156] {aka CD140A, PDGFR-2, PDGFR2}, ATRX (ATRX chromatin remodeler) [NCBI Gene 546] {aka JMS, MRX52, RAD54, RAD54L, XH2, XNP}, NF1 (neurofibromin 1) [NCBI Gene 4763] {aka NFNS, VRNF, WSS}, Fgf2 (fibroblast growth factor 2) [NCBI Gene 14173] {aka Fgf-2, Fgf2a, Fgfb, bFGF}, IDH1 (isocitrate dehydrogenase (NADP(+)) 1) [NCBI Gene 3417] {aka HEL-216, HEL-S-26, IDCD, IDH, IDP, IDPC}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}
- **Diseases:** brain swelling (MESH:D001929), intracranial lesions (MESH:D020765), breast cancer (MESH:D001943), hypoxic (MESH:D002534), organoids (MESH:D054000), acute myeloid leukaemia (MESH:D054218), IDH-A tumours (MESH:D009369), non-small cell lung cancer (MESH:D002289), WHO (MESH:D000092124), necrotic (MESH:D009336), NOD (MESH:D020191), Glioblastoma (MESH:D005909), Glioblastoma metastasis (MESH:D009362), epilepsy (MESH:D004827), Malignant tumours of the CNS (MESH:D016543), MES (MESH:C535700), inflammatory (MESH:D007249), invasive tumours (MESH:D009361), Brain tumour (MESH:D001932), leukaemia (MESH:D015458), AA) III (MESH:C566236), NSC (OMIM:617394), NPC (MESH:D052556), cytotoxicity (MESH:D064420), death (MESH:D003643), neurological deficits (MESH:D009461), Adult Gliomas (MESH:D020339), lung cancer (MESH:D008175), Diffuse astrocytoma (MESH:D001254), GVHD (MESH:D006086), oncological (MESH:D000072716), brain disorder (MESH:D001927), O (MESH:C535508), hypoxia (MESH:D000860), haemorrhages (MESH:D006470), infection (MESH:D007239), Oligodendroglioma (MESH:D009837), deficient (MESH:D007153), SCID (MESH:D045169), melanoma (MESH:D008545), Diffuse gliomas (MESH:D005910), HGG (MESH:D008228), cholangiocarcinoma (MESH:D018281),  (MESH:D004195)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Mutations:** Arg 132
- **Cell lines:** LN-18 — Homo sapiens (Human), Glioblastoma, Cancer cell line (CVCL_0392), U-87MG — Homo sapiens (Human), Glioblastoma, Cancer cell line (CVCL_0022), U251 — Homo sapiens (Human), Astrocytoma, Cancer cell line (CVCL_0021), LN-229 — Homo sapiens (Human), Glioblastoma, Cancer cell line (CVCL_0393), B-27 — Mus musculus (Mouse), Hybridoma (CVCL_J172)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC7831916/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC7831916/full.md

## References

211 references — full list in the complete paper: https://tomesphere.com/paper/PMC7831916/full.md

---
Source: https://tomesphere.com/paper/PMC7831916